Catalyst Event

Novartis AG (NVS) · Earnings Release

From KEDI Global Longevity Bio Index (KGLB)

4/28/2026, 12:00:00 AM

Earnings ReleaseSentiment: Negative

Q1 2026 earnings and revenue missed analyst expectations on April 28, 2026. Net sales were $13.1B (-1% reported, -5% constant currency) and core EPS was $1.99 (-13% reported), primarily due to US generic competition for the drug Entresto. The stock price declined following the announcement.

Korean Translation

2026년 4월 28일 발표된 1분기 실적 및 매출이 시장 예상치를 하회함. 미국 내 심부전 치료제 엔트레스토(Entresto)의 제네릭 경쟁 심화로 순매출은 131억 달러(-1%, 고정환율 기준 -5%), 핵심 EPS는 1.99달러(-13%)를 기록함. 발표 후 주가는 하락함.

Related Recent Events

View Full Timeline